Thiopurine S-methyltransferase genotypic analysis in autoimmune bullous diseases

European Journal of Dermatology

Volumn 18, Issue 5, 2008, Pages 512-517

  Bezier, Maud ^a   Reguiai, Ziad ^a   Vitry, Fabien ^b   Broly, Franck ^c   Bernard, Philippe ^a  

^a SERVICE DE DERMATOLOGIE   (France)

^b HÔPITAL MAISON BLANCHE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Autoimmune bullous disease; Genotypic analysis; Thiopurine S methyl transferase

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; DAPSONE; IMMUNOGLOBULIN; TETRACYCLINE DERIVATIVE; THIOPURINE METHYLTRANSFERASE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BULLOUS PEMPHIGOID; BULLOUS SKIN DISEASE; DIARRHEA; DISEASE PREDISPOSITION; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EPIDERMOLYSIS BULLOSA ACQUISITA; FEMALE; GASTROINTESTINAL SYMPTOM; GENE ACTIVITY; GENE FREQUENCY; GENE MUTATION; GENETIC VARIABILITY; HEMATOLOGIC DISEASE; HEMOLYSIS; HEPATITIS; HUMAN; LEUKOPENIA; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MUCOUS MEMBRANE PEMPHIGOID; NAUSEA; NEUTROPENIA; PANCREATITIS; PLASMAPHERESIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 52649135127     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: 10.1684/ejd.2008.0473     Document Type: Article

References (32)

1. Patel AA, Swerlick RA, McCall CO. Azathioprine in dermatology: The past, the present, and the future. J Am Acad Dermatol 2006; 55: 369-89.
2. Tan BB, Lear JT, Gawkrodger DJ, English JSC. Azathioprine in dermatology: a survey of current practice in the U.K. Br J Dermatol 1997; 136: 351-5.
3. Scerri L. Azathioprine in dermatological practice. An overview with special emphasis on its use in non-bullous inflammatory dermatoses. Adv Exp Med Biol 1999; 455: 343-8.
4. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 1995; 131: 193-7.
5. Snow JL, Gibson LE. A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients. J Am Acad Dermatol 1995; 32: 114-6.
6. Jackson AP, Hall AG, McLelland J. Thiopurine methyltransferase levels should be measured before commencing patients on azathioprine. Br J Dermatol 1997; 136: 133-4.
7. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989; 46: 149-54.
8. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocte thiopurine methyltrasferase activity. Am J Hum Genet 1980; 32: 651-62.
9. Bessard G, Hardy G, Chartier A, Stanke-Labesque F. Genetic polymorphism and treatment of chronic bowel inflammatory diseases: the example of azathioprine. Therapie 2004; 59: 71-5.
10. Yates CR, Krynetski Y, Loennechen T, Fessing MY, Thai HL, Pui CH, et al. Molecular diagnosis of thiopurine s-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126: 608-14.
11. Spire-Vayron de la Moureyre C, Debuysere H, Mastain B, Vinner E, Marez D, Lo Guidice JM, et al. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br J Pharmacol 1998; 125: 879-87.
12. Spire-Vayron de la Moureyre C, Debuysere H, Sabbagh N, Marez D, Vinner E, Chevalier ED, et al. Detection of known and new mutations in the Thiopurine S-Methyltransferase gene by single-strand conformation polymorphism analysis. Hum Mutat 1998; 12: 177-85.
13. Murphy LA, Atherton D. A retrospective evaluation of azathioprine in severe chilhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression. B J Dermatol 2002; 147: 308-15.
14. Meggitt SJ, Gra JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate to severe atopic eczema: a double-blind, randomised controlled trial. Lancet 2006; 367: 839-46.
15. Murphy LA, Atherton DJ. Azathioprine as a treatment for severe atopic eczema in children with a partial thiopurine methyltransferase (TPMT) deficiency. Pediatr Dermatol 2003; 20: 531-4.
16. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992; 43: 329-39.
17. Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025-30.
18. Hamdan-khalil R, Allorge D, Lo-Guidice JM, Cauffiez C, Chevalier D, Spire C, et al. In vitro characterization of four novel non-functional variants of the thiopurine S-methytransferase. Biochem Biophys Res Commun 2003; 309: 1005-10.
19. Hamdan-Khalil R, Gala JL, Allorge D, Lo-Guidice JM, Horsmans Y, Houdret N, et al. Identification and functional analysis of two rare allelic variants of the thiopurine S-methltransferase gene, TPMT16 and TPMT19. Bioch Pharmacol 2005; 69: 525-9.
20. Tavadia SMB, Mydlarski PR, Reis MD, Mittmann N, Pinkerton PH, Shear N, et al. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J Am Acad Dermatol 2000; 42: 628-32.
21. Anstey AV, Wakelin S, Reynolds NJ, British Association of Dermatologists Therapy, Guidelines and Audit Subcommittee. Guidelines for prescription azathioprine in dermatology. Br J Dermatol 2004; 151: 1123-32.
22. Joly P, Mouquet H, Roujeau JC, D'Incan M, Gilbert D, Jacquot S, et al. A single cycle of rituxmab for the treatment of severe pemphigus. N Engl Med 2007; 357: 545-52.
23. Bara C, Maillard H, Briand N, Celerier P. Methotrexate for bullous pemphigoid: preliminary study. Arch Dermatol 2003; 139: 1506-7.
24. Dereure O, Bessis D, Guillot B, Guilhou JJ. Treatment of bullous pemphigoid by low-dose methotrexate associated with short-term potent topical steroids: an open prospective study of 18 cases. Arch Dermatol 2002; 138: 1255-6.
25. Black AJ, McLeod HL, Capell HA, Powrie RH, Matowe LK, Pritchard SC, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998; 129(9): 716-8.
26. Jun JB, Cho DY, Kong C, Bae SC. Thiopurine S-methyltransferase polymorphisms and the relationship between the mutant alleles and the adverse effects in systemic lupus erythematosus patients taking azathioprine. Clin Exp Rheumatol 2005; 23: 873-6.
27. Zelinkova Z, Derijks LJ, Stokkers PC, Vogels EW, Van Kampen AH, Curvers WL, et al. Inosine triphosphate pyrophosphatase and thiopurine S-methyltransferase genotypes relationship to azathioprine-incluced myelosuppression. Clin Gastroenterol Hepatol 2006; 4: 44-9.
28. Kurzawski M, Dziewanowski K, Gawronska-Szklarz B, Domanski L, Drozdzik M. The impact of thiopurine S-methyltransferase polymorphism on azathioprine-induced myelotoxicity in renal transplant recipients. Ther Drug Monit 2005; 27: 435-41.
29. Gisbert JP, Nino P, Rodrigo L, Cara C, Guijarro LG. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am J Gastroenterol 2006; 101: 2769-76.
30. Stolk JN, Boerbooms AM, de Abreu RA, de Koning DG, van Beusekom HJ, Muller WH, et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum 1998; 41(10): 1858-66.
31. Stocco G, Martelossi S, Barabino A, Fontana M, Lionetti P, Decorti G, et al. TPMT genotype and the use of thiopurines in paediatric inflammatory bowel disease. Dig Liver Dis 2005; 37: 940-5.
32. Pandya B, Thomson W, Poulton K, Payne BD, Qasim F. Azathioprine toxicity and thiopurine methyltransterase genotype in renal transplant patients. Transplant Proc 2002; 34(5): 1642-5.